According to Zacks, “Oncorus Inc. is a clinical stage biopharmaceutical company. It is focused on developing viral immunotherapies to transform outcomes for cancer patients. The company’s product candidate includes ONCR-177, which is in clinical stage. Oncorus Inc. is based in CAMBRIDGE, Mass. “
Several other equities research analysts have also commented on ONCR. HC Wainwright started coverage on shares of Oncorus in a research report on Monday, March 28th. They set a buy rating and a $7.00 price target for the company. Maxim Group lowered their price target on Oncorus from $20.00 to $7.00 in a research report on Thursday, March 10th.
Oncorus (NASDAQ:ONCR – Get Rating) last issued its quarterly earnings data on Wednesday, March 9th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.06). Equities research analysts forecast that Oncorus will post -2.83 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Deep Track Capital LP purchased a new position in Oncorus during the 4th quarter worth approximately $3,162,000. BlackRock Inc. raised its stake in Oncorus by 22.5% during the fourth quarter. BlackRock Inc. now owns 1,354,009 shares of the company’s stock valued at $7,135,000 after buying an additional 248,560 shares in the last quarter. Altium Capital Management LP acquired a new stake in shares of Oncorus during the 3rd quarter worth approximately $1,794,000. Geode Capital Management LLC increased its position in Oncorus by 33.8% in the 4th quarter. Geode Capital Management LLC now owns 296,471 shares of the company’s stock valued at $1,562,000 after acquiring an additional 74,870 shares during the period. Finally, Morgan Stanley boosted its stake in Oncorus by 697.0% during the 3rd quarter. Morgan Stanley now owns 77,197 shares of the company’s stock valued at $721,000 after purchasing an additional 67,511 shares in the last quarter. Institutional investors own 83.21% of the company’s stock.
Oncorus Company Profile (Get Rating)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.